Barclays analyst Luke Sergott raised the firm’s price target on Thermo Fisher (TMO) to $585 from $550 and keeps an Overweight rating on the shares as part of a Q3 preview for the life science tools and diagnostics group. The firm views the companies’ end markets as stable with improvements likely going forward. In addition, investment sentiment “feels bottomed” as share valuations have come down, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Early notable gainers among liquid option names on October 1st
- Thermo Fisher: Strong Buy Rating Backed by Robust Performance and Growth Potential
- Vaxcyte to establish fill-finish manufacturing in North Carolina
- Harvard Bioscience expands distribution agreement with Fisher Scientific
- Apple downgraded, Nvidia upgraded: Wall Street’s top analyst calls